State Street Corp Purchases 57,943 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

State Street Corp boosted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 48.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 178,246 shares of the company’s stock after purchasing an additional 57,943 shares during the quarter. State Street Corp owned about 0.28% of Corvus Pharmaceuticals worth $941,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in CRVS. Nwam LLC acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $53,000. Avity Investment Management Inc. raised its position in shares of Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after acquiring an additional 16,000 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at $89,000. Cubist Systematic Strategies LLC bought a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth $44,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after purchasing an additional 53,809 shares during the period. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ CRVS opened at $5.43 on Friday. The company has a fifty day moving average price of $7.72 and a 200 day moving average price of $5.26. The firm has a market cap of $348.92 million, a PE ratio of -5.84 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00.

Wall Street Analyst Weigh In

Several research firms have weighed in on CRVS. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Oppenheimer lifted their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright began coverage on shares of Corvus Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $11.00 target price for the company. LADENBURG THALM/SH SH lifted their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.